StockData

TFA Therapeutics, Inc. (RAJAF) stock

RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026Score 7/30
$9.18+0.00 (0.00%)

Close on Oct 16, 2026Market cap –P/E –Yield –

TFA Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

TFA Therapeutics's operating cash flow for the twelve months ending Dec 31, 2023 was $359.72K. For fiscal 2025 it was -$35.85K, down 111.5% from the year before. The highest annual figure on record is $359.72K in fiscal 2023.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$35.85K-111.5%
FY2024Dec 31, 2024$312.01K-13.3%
FY2023Dec 31, 2023$359.72K–
FY2022Dec 31, 2022-$321.38K–
FY2021Dec 31, 2021-$365.36K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023-$1.23M–
Q4 FY2022Dec 31, 2022-$110.82K–

More TFA Therapeutics figures

See a number that looks wrong?